Recently, Yu et al. detected the expression of IL-22 in new lesions and reported that this was significantly higher in the peripheral blood of recurrent NSCLC patients, when compared to that at baseline [18]. The gene discussed is IL22; the disease is non-small cell lung carcinoma.